Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
En resumen: Estos frmacos han emergido como una herramienta teraputica revolucionaria en el manejo del peso y el tratamiento de la obesidad
Plaintiffs allege the drug labels failed to disclose the risk of NAION or other severe vision complications, depriving patients of the ability to make informed treatment decisions
GLP-1 Story Continues Here are the key figures since Q2 2024: Q2 2024: GLP-1 revenue: $12 million Total revenue: $325 million Share of GLP-1 revenue: 4 % Q3 2024: GLP-1 revenue: $55 million* Total revenue: $441 million Share of GLP-1 revenue: 12 % Q4 2024: GLP-1 revenue: $162 million* Total revenue: $488 million Share of GLP-1 revenue: 33 % Q1 2025: GLP-1 revenue: $ 230 million Total revenue: $596 million Share of GLP-1 revenue: 39 % Q2 2025: GLP-1 revenue: $190 million Total revenue: $545 million Share of GLP-1 revenue: 35 % * Estimate based on the $229M GLP-1 revenue for FY 2024 Revenue Momentum Stalls Amid GLP-1 Reliance Historically Hims has issued conservative guidance and then surpassed the top end of its range
Both phases are characterized by high metabolic demands
US$ 29.22
US$ 20.61
US$ 23.05
